医学
内科学
危险系数
长春瑞滨
肿瘤科
乳腺癌
化疗
艾瑞布林
吉西他滨
转移性乳腺癌
癌症
外科
胃肠病学
置信区间
顺铂
作者
Aditya Bardia,Sara A. Hurvitz,Sara M. Tolaney,Delphine Loirat,Kevin Punie,Mafalda Oliveira,Adam Brufsky,Sagar Sardesai,Kevin Kalinsky,Amelia Zelnak,Robert Weaver,Tiffany A. Traina,Florence Dalenc,Philippe Aftimos,Filipa Lynce,Sami Diab,Javier Cortés,Joyce O’Shaughnessy,Véronique Dièras,Cristiano Ferrario
标识
DOI：10.1056/nejmoa2028485
摘要
Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer. Myelosuppression and diarrhea were more frequent with sacituzumab govitecan. (Funded by Immunomedics; ASCENT ClinicalTrials.gov number, NCT02574455; EudraCT number, 2017-003019-21.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
科研狗
大力的灵雁
蓝莓橘子酱
gyh
你嵙这个期刊没买
干净的琦
penxyy
负责的寒梅
tiptip
热心市民小杨
Dean
橘x
Gauss
蓝天
Microwhale
初晴
殷勤的紫槐
123
子车茗
皖公网安备34019202002308
